Short and long term treatment of asthma with intravenous nutrients
- PMID: 15144562
- PMCID: PMC420479
- DOI: 10.1186/1475-2891-3-6
Short and long term treatment of asthma with intravenous nutrients
Abstract
Background: Asthma is an increasing problem in this country and others. Although medications for the treatment of asthma abound and are improving, there are inherent risks and side effects with all of them. Intravenous magnesium has been employed in the treatment of acute asthma, but its use has not become universal, nor has it been studied for the treatment of chronic asthma. It is known to be a safe drug with minimal side effects. In this study, the author investigates the use of magnesium and other nutrients in the treatment of both acute and chronic asthma.
Methods: In this non-blinded outcome study, following informed consent, forty-three (43) randomly selected volunteer patients with both acute and chronic asthma were treated with IV infusions described herein. All patients were observed with spirometry 10 minutes post-infusion; two sub-groups of patients were also observed after multiple infusions over a short period of time (less than one month) and a longer period of time (average 5.8 months). Pulmonary function was analyzed by spirometric testing with pre- and post-infusion spirometric measurements with the pre/post group. For longer term (Trend) patients, baseline spirometry measurements were compared to spirometry measurements after patients had received multiple infusions over a period of time. Eight (8) patients were measured for both pre/post and Trend data.
Results: The 38 pre-infusion/post-infusion patients with acute and chronic asthma demonstrated an overall average improvement (percentage improvement in percent predicted) of 45%. The 13 patients measured for improvement over time (Trend data, average duration 5.82 months), demonstrated an overall average improvement (percentage improvement in percent predicted) of 57%. Of the 13 patients in the multiple infusion group, 9 patients who received longer-term therapy (average duration of 12.58 months) for chronic asthma demonstrated an overall average improvement of 95% (percentage improvement in percent predicted).
Conclusion: The use of intravenous treatment with multiple nutrients, including magnesium, for acute and chronic asthma may be of considerable benefit. Pulmonary function improved progressively the longer patients received treatment.
Similar articles
-
Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial.J Pediatr. 1996 Dec;129(6):809-14. doi: 10.1016/s0022-3476(96)70023-9. J Pediatr. 1996. PMID: 8969721 Clinical Trial.
-
Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma.Chest. 1995 Jun;107(6):1576-81. doi: 10.1378/chest.107.6.1576. Chest. 1995. PMID: 7781349 Clinical Trial.
-
Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma.Arch Pediatr Adolesc Med. 2000 Oct;154(10):979-83. doi: 10.1001/archpedi.154.10.979. Arch Pediatr Adolesc Med. 2000. PMID: 11030848 Clinical Trial.
-
Clevidipine: a review of its use in the management of acute hypertension.Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Am J Cardiovasc Drugs. 2009. PMID: 19331440 Review.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
References
-
- Sly RM, O'Donnell R. Stabilization of asthma mortality. Comment in Ann Allergy Asthma Immunol. 1997;78:347–54. Ann. Aller. Asthma & Immunol. 1997;78 (4): 347-54. - PubMed
-
- Lang DM. Trends in US asthma mortality: good news and bad news. Comment on: Ann Allergy Asthma Immunol. 1997;78:333–7. Ann. Aller. Asthma Immunol. 1997;78(4): 333-7. - PubMed
-
- Beasley R, Nishima S, Pearce N, Crane J. Beta-agonist therapy and asthma mortality in Japan [letter] Lancet. 1998;351:1406–7. - PubMed
LinkOut - more resources
Full Text Sources